Trastuzumab

Overview

Trastuzumab, sold under the brand name Herceptin among others, is a monoclonal antibody used to treat breast cancer and stomach cancer. It is specifically used for cancer that is HER2 receptor positive. It may be used by itself or together with other chemotherapy medication. Trastuzumab is given by slow injection into a vein and injection just under the skin.[1–5] WP

Common side effects include fever, infection, cough, headache, trouble sleeping, and rash. Other severe side effects include heart failure, allergic reactions, and lung disease. Use during pregnancy may harm the baby. Trastuzumab works by binding to the HER2 receptor and slowing down cell replication.[1][6] WP

Trastuzumab was approved for medical use in the United States in September 1998, and in the European Union in August 2000. It is on the World Health Organization's List of Essential Medicines.[4][7][8] WP

Drug class

Antineoplastic agent WP

From the Wikipedia article's infobox.

Uses, dosage and effects

Medical uses

The safety and efficacy of trastuzumab-containing combination therapies (with chemotherapy, hormone blockers, or lapatinib) for the treatment of metastatic breast cancer. The overall hazard ratios (HR) for overall survival and progression free survival were 0.82 and 0.61, respectively. It was difficult to accurately ascertain the true impact of trastuzumab on survival, as in three of the seven trials, over half of the patients in the control arm were allowed to cross-over and receive trastuzumab after their cancer began to progress. Thus, this analysis likely underestimates the true survival benefit associated with trastuzumab treatment in this population.[9][10] WP⚠ Wikipedia itself has flagged this text: clarification needed.

In early-stage HER2-positive breast cancer, trastuzumab-containing regimens improved overall survival (Hazard ratio (HR) = 0.66) and disease-free survival (HR = 0.60). Increased risk of heart failure (RR = 5.11) and decline in left ventricular ejection fraction (relative risk RR = 1.83) were seen in these trials as well. Two trials involving shorter term treatment with trastuzumab did not differ in efficacy from longer trials, but produced less cardiac toxicity.[11] WP

The original studies of trastuzumab showed that it improved overall survival in late-stage (metastatic) HER2-positive breast cancer from 20.3 to 25.1 months. In early-stage HER2-positive breast cancer, it reduces the risk of cancer returning after surgery. The absolute reduction in the risk of cancer returning within three years was 9.5%, and the absolute reduction in the risk of death within 3 years was reduced by 3%. However, it increases serious heart problems by an absolute risk of 2.1%, though the problems may resolve if treatment is stopped.[11][12] WP

Trastuzumab has had a "major impact in the treatment of HER2-positive metastatic breast cancer." The combination of trastuzumab with chemotherapy has been shown to increase both survival and response rate, in comparison to trastuzumab alone.[13][14] WP

It is possible to determine the "erbB2 status" of a tumor, which can be used to predict efficacy of treatment with trastuzumab. If it is determined that a tumor is overexpressing the erbB2 oncogene and the patient has no significant pre-existing heart disease, then a patient is eligible for treatment with trastuzumab. It is surprising that although trastuzumab has great affinity for HER2 and high doses can be administered (because of its low toxicity), 70% of HER2+ patients do not respond to treatment. In fact resistance to the treatment develops rapidly, in virtually all patients. A mechanism of resistance involves failure to downregulate p27^Kip1 as well as suppressing p27 translocation to the nucleus in breast cancer, enabling cdk2 to induce cell proliferation.[15][16][17] WP

In May 2021, the FDA approved pembrolizumab in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy for the first-line treatment of people with locally advanced unresectable or metastatic HER2 positive gastric or gastroesophageal junction (GEJ) adenocarcinoma.[18] WP

Duration of treatment

The optimal duration of add-on trastuzumab treatment after surgery for early breast cancer is unknown. One year of treatment is generally accepted based on clinical trial evidence that demonstrated the superiority of one-year treatment over none. However, a small Finnish trial also showed similar improvement with nine weeks of treatment over no therapy. Because of the lack of direct head-to-head comparison in clinical trials, it is unknown whether a shorter duration of treatment may be just as effective (with fewer side effects) than the accepted practice of treatment for one year. Debate about treatment duration has become a relevant issue for many public health policy makers because administering trastuzumab for a year is very expensive. Consequently, some countries with a taxpayer-funded public health system, such as New Zealand, chose to fund limited adjuvant therapy. However, subsequently New Zealand has revised its policy and now funds trastuzumab treatment for up to 12 months.[19–23] WP

Risks and side effects

Adverse effects

Some of the common side effects of trastuzumab are flu-like symptoms (such as fever, chills and mild pain), nausea and diarrhea.[24] WP

One of the more serious complications of trastuzumab is its effect on the heart, although this is rare. In 2–7% of cases, trastuzumab is associated with cardiac dysfunction, which includes congestive heart failure. As a result, regular cardiac screening with either a MUGA scan or echocardiography is commonly undertaken during the trastuzumab treatment period. The decline in ejection fraction appears to be reversible.[24][25][26] WP

Trastuzumab downregulates neuregulin-1 (NRG-1), which is essential for the activation of cell survival pathways in cardiomyocytes and the maintenance of cardiac function. NRG-1 activates the MAPK pathway and the PI3K/AKT pathway as well as focal adhesion kinases (FAK). These are all significant for the function and structure of cardiomyocytes. Trastuzumab can therefore lead to cardiac dysfunction.[27] WP

Trastuzumab may harm a developing fetus.[28][29] WP

Pharmacology

Mechanism of action

The HER2 gene (also known as HER2/neu and ErbB2 gene) is amplified in 20–30% of early-stage breast cancers. Trastuzumab is a monoclonal antibody targeting HER2, inducing an immune-mediated response that causes internalization and recycling of HER2. It may also upregulate cell cycle inhibitors such as p21^Waf1 and p27^Kip1.[16][30] WP

The HER2 pathway promotes cell growth and division when it is functioning normally; however, when it is overexpressed, cell growth accelerates beyond its normal limits. In some types of cancer, the pathway is exploited to promote rapid cell growth and proliferation and hence tumor formation. The EGF pathway includes the receptors HER1 (EGFR), HER2, HER3, and HER4; the binding of ligands (e.g. EGF etc.) to HER receptors is required to activate the pathway. The pathway initiates the MAP kinase pathway as well as the PI3 kinase/AKT pathway, which in turn activates the NF-κB pathway. In cancer cells the HER2 protein can be expressed up to 100 times more than in normal cells (2 million versus 20,000 per cell).[31][32][33] WP

The HER receptors are proteins that are embedded in the cell membrane and communicate molecular signals from outside the cell (molecules called EGFs) to inside the cell, and turn genes on and off. The HER (human epidermal growth factor receptor) protein, binds to human epidermal growth factor, and stimulates cell proliferation. In some cancers, notably certain types of breast cancer, HER2 is over-expressed and causes cancer cells to reproduce uncontrollably.[12] WP

HER2 is localized at the cell surface, and carries signals from outside the cell to the inside. Signaling compounds called mitogens (specifically EGF in this case) arrive at the cell membrane, and bind to the extracellular domain of the HER family of receptors. Those bound proteins then link (dimerize), activating the receptor. HER2 sends a signal from its intracellular domain, activating several different biochemical pathways. These include the PI3K/Akt pathway and the MAPK pathway. Signals on these pathways promote cell proliferation and the growth of blood vessels to nourish the tumor (angiogenesis). ERBB2 is the preferred dimerization partner for the other family members and ERBB2 heterodimers signaling is stronger and longer acting compared to heterodimers between other ERBB members. It has been reported that Trastuzumab induces the formation of complementarity-determining regions (CDRs) leading to surface redistribution of ERBB2 and EGFR in CDRs and that the ERBB2-dependent MAPK phosphorylation and EGFR/ERBB1 expression are both required for CDR formation. CDR formation requires activation of both the protein regulator of actin polymerization N-WASP, mediated by ERK1/2, and of the actin-depolymerizing protein cofilin, mediated by EGFR/ERBB1. Furthermore, this latter event may be inhibited by the negative cell motility regulator p140Cap, as we found that p140Cap overexpression led to cofilin deactivation and inhibition of CDR formation.[34] WP

Normal cell division—mitosis—has checkpoints that keep cell division under control. Some of the proteins that control this cycle are called cdk2 (CDKs). Overexpression of HER2 sidesteps these checkpoints, causing cells to proliferate in an uncontrolled fashion.[17] WP

Trastuzumab binds to domain IV of the extracellular segment of the HER2/neu receptor. Monoclonal antibodies that bind to this region have been shown to reverse the phenotype of HER2/neu expressing tumor cells. Cells treated with trastuzumab undergo arrest during the G1 phase of the cell cycle so there is reduced proliferation. It has been suggested that trastuzumab does not alter HER-2 expression, but downregulates activation of AKT. In addition, trastuzumab suppresses angiogenesis both by induction of antiangiogenic factors and repression of proangiogenic factors. It is thought that a contribution to the unregulated growth observed in cancer could be due to proteolytic cleavage of HER2/neu that results in the release of the extracellular domain. One of the most relevant proteins that trastuzumab activates is the tumor suppressor p27^Kip1, also known as CDKN1B. Trastuzumab has been shown to inhibit HER2/neu ectodomain cleavage in breast cancer cells.[16][17][35][36][37] WP

Experiments in laboratory animals indicate that antibodies, including trastuzumab, when bound to a cell, induce immune cells to kill that cell, and that such antibody-dependent cell-mediated cytotoxicity is another important mechanism of action.[38] WP

History

History

The drug was first discovered by scientists including Axel Ullrich and H. Michael Shepard at Genentech, Inc. in South San Francisco, CA. Earlier discovery about the neu oncogene by Robert Weinberg's lab and the monoclonal antibody recognizing the oncogenic receptor by Mark Greene's lab also contributed to the establishment of HER2 targeted therapies. Dr. Dennis Slamon subsequently worked on trastuzumab's development. A book about Dr. Slamon's work was made into a television film called Living Proof, that premiered in 2008. Genentech developed trastuzumab jointly with UCLA, beginning the first clinical trial with 15 women in 1992. By 1996, clinical trials had expanded to over 900 women, but due to pressure from advocates based on early success, Genentech worked with the FDA to begin a lottery system allowing 100 women each quarter access to the medication outside the trials. Herceptin was Fast-tracked by the FDA and gained approval in September 1998.[7][39–43] WP

Biocon Ltd and its partner Mylan obtained regulatory approval to sell a biosimilar in 2014, but Roche contested the legality of the approval; that litigation ended in 2016, and Biocon and Mylan each introduced their own branded biosimilars.[44] WP

Legal status

Economics

Trastuzumab costs about US$70,000 for a full course of treatment.[45] WP

Australia has negotiated a lower price of A$50,000 per course of treatment.[46] WP

Since October 2006, trastuzumab has been made available for Australian women and men with early-stage breast cancer via the Pharmaceutical Benefits Scheme. This is estimated to cost the country over A$470 million for 4–5 years supply of the drug.[47] WP

Roche has agreed with Emcure in India to make an affordable version of this cancer drug available to the Indian market.[48] WP⚠ Wikipedia itself has flagged this text: when?.

Roche has changed the brand name of the drug and has re-introduced an affordable version of the same in the Indian market. The new drug named Herclon would cost approximately RS75,000 INR (US$ 870) in the Indian market.[49] WP⚠ Wikipedia itself has flagged this text: clarification needed.⚠ Wikipedia itself has flagged this text: when?.

On 16 September 2014, Genentech notified hospitals in the United States that, as of October, trastuzumab could only be purchased through their selected specialty drugs distributors not through the usual general line wholesalers. By being forced to purchase through specialty pharmacies, hospitals lost rebates from the big wholesalers and the ability to negotiate cost-minus discounts with their wholesalers.[50] WP

Biosimilars

By 2014, around 20 companies, particularly from emerging markets, were developing biosimilar versions of trastuzumab after Roche/Genentech's patents expired in 2014 in Europe, and in 2019 in the United States.[51] WP

In January 2015, BIOCAD announced the first trastuzumab biosimilar approved by the Ministry of Health of the Russian Federation. Iran also approved its own version of the monoclonal antibody in January 2016, as AryoTrust, and announced its readiness to export the drug to other countries in the Middle-East and Central Asia when trade sanctions were lifted.[52][53] WP⚠ Wikipedia itself has flagged this text: clarification needed.

In 2016, the investigational biosimilar MYL-1401O showed comparable efficacy and safety to the Herceptin branded trastuzumab. Trastuzumab-dkst (Ogivri, Mylan GmbH) was approved in the United States in December 2017, to "treat people with breast cancer or gastric or gastroesophageal junction adenocarcinoma whose tumors overexpress the HER-2 gene." Ogivri was authorized for medical use in the European Union in December 2018.[54–58] WP

In November 2017, the European Commission authorized Ontruzant, a biosimilar from Samsung Bioepis Co., Ltd, for the treatment of early breast cancer, metastatic breast cancer and metastatic gastric cancer. Ontruzant is the first trastuzumab biosimilar to receive regulatory approval in the European Union.[59][60][61] WP

Herzuma was authorized for medical use in the European Union in February 2018. Herzuma, a trastuzumab biosimilar, was approved in the United States in December 2018. The approval was based on comparisons of extensive structural and functional product characterization, animal data, human pharmacokinetic, clinical immunogenicity, and other clinical data demonstrating that Herzuma is biosimilar to US Herceptin. Herzuma has been approved as a biosimilar, not as an interchangeable product.[62–66] WP

Kanjinti was authorized for medical use in the European Union in May 2018.[67][68] WP

Trazimera was authorized for medical use in the European Union in July 2018.[69] WP

Ogivri was approved for medical use in Canada in May 2019.[70] WP

Trazimera was approved for medical use in Canada in August 2019.[71] WP

Herzuma was approved for medical use in Canada in September 2019.[72] WP

Kanjinti was approved for medical use in Canada in February 2020.[73] WP

Zercepac was authorized for medical use in the European Union in July 2020.[74][75] WP

Trastucip and Tuzucip were approved for medical use in Australia in July 2022.[76] WP

In September 2023, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Herwenda, intended for the treatment of HER2-positive breast and gastric cancer. The applicant for this medicinal product is Sandoz GmbH. Herwenda was authorized for medical use in the European Union in November 2023.[77][78][79] WP

Trastuzumab-strf (Hercessi) was approved for medical use in the United States in April 2024.[80] WP

In July 2024, the CHMP adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Tuznue, intended for the treatment of breast and gastric cancer. The applicant for this medicinal product is Prestige Biopharma Belgium BVBA. Tuznue is a biosimilar medicinal product. Tuznue was authorized for medical use in the European Union in September 2024.[81][82] WP

Adheroza was approved for medical use in Canada in August 2024.[83][84] WP

In April 2025, the CHMP adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Dazublys, intended for the treatment of breast and gastric cancer. The applicant for this medicinal product is CuraTeQ Biologics s.r.o. Dazublys is a biosimilar medicinal product that is highly similar to the reference product Herceptin (trastuzumab), which was authorized in the EU in August 2000. Dazublys was authorized for medical use in the EU in June 2025.[85][86] WP

Related conjugates

Trastuzumab is also a component of some antibody-drug conjugates, such as trastuzumab emtansine, and trastuzumab deruxtecan.[87][88][89] WP

Chemistry

Harm reduction information

No harm reduction data is on file for this compound yet. That means no dose, timing or combination data from PsychonautWiki or TripSit. Please don't guess a dose from similar compounds. If you have taken it and feel unwell, contact emergency services or a poison control center.

User reports

Pop culture

No references added yet.

Sources

1. Other Trastuzumab
2. Journal / agency Herceptin- trastuzumab kit Herceptin- trastuzumab injection, powder, lyophilized, for solution. 30 September 2019
3. Journal / agency FDA approves first biosimilar for the treatment of certain breast and stomach cancers. 10 September 2019
4. Journal / agency Herceptin EPAR. 17 September 2018
5. Other British national formulary: BNF 69. 2015
6. Other Trastuzumab Pregnancy and Breastfeeding Warnings
7. Journal / agency Trastuzumab Product Approval Information - Licensing Action 9/25/98. 18 December 2015
8. Other The selection and use of essential medicines 2023: web annex A: World Health Organization model list of essential medicines: 23rd list (2023). 2023
9. Journal / agency Balduzzi S, Mantarro S, Guarneri V, Tagliabue L, Pistotti V, Moja L, D'Amico R. Trastuzumab-containing regimens for metastatic breast cancer. The Cochrane Database of Systematic Reviews. June 2014. doi:10.1002/14651858.CD006242.pub2 · PMID 24919460 · PMC6464904
10. Journal / agency Wilcken N. Treating metastatic breast cancer: the evidence for targeted therapy. The Cochrane Database of Systematic Reviews. June 2014. doi:10.1002/14651858.ED000083 · PMID 25032250 · PMC10845883
11. Journal / agency Moja L, Tagliabue L, Balduzzi S, Parmelli E, Pistotti V, Guarneri V, D'Amico R. Trastuzumab containing regimens for early breast cancer. The Cochrane Database of Systematic Reviews. April 2012. doi:10.1002/14651858.CD006243.pub2 · PMID 22513938 · PMC6718210
12. Journal / agency Hudis CA. Trastuzumab--mechanism of action and use in clinical practice. The New England Journal of Medicine. July 2007. doi:10.1056/NEJMra043186 · PMID 17611206
13. Journal / agency Tan AR, Swain SM. Ongoing adjuvant trials with trastuzumab in breast cancer. Seminars in Oncology. October 2003. doi:10.1053/j.seminoncol.2003.08.008 · PMID 14613027
14. Journal / agency Nahta R, Esteva FJ. HER-2-targeted therapy: lessons learned and future directions. Clinical Cancer Research. November 2003. PMID 14613984
15. Journal / agency Yu D, Hung MC. Overexpression of ErbB2 in cancer and ErbB2-targeting strategies. Oncogene. December 2000. doi:10.1038/sj.onc.1203972 · PMID 11156524
16. Journal / agency Le XF, Pruefer F, Bast RC. HER2-targeting antibodies modulate the cyclin-dependent kinase inhibitor p27Kip1 via multiple signaling pathways. Cell Cycle. January 2005. doi:10.4161/cc.4.1.1360 · PMID 15611642
17. Journal / agency Kute T, Lack CM, Willingham M, Bishwokama B, Williams H, Barrett K, Mitchell T, Vaughn JP. Development of Herceptin resistance in breast cancer cells. Cytometry. Part A. February 2004. doi:10.1002/cyto.a.10095 · PMID 14750129
18. Journal / agency FDA grants accelerated approval to pembrolizumab for HER2-positive gastric cancer. 5 May 2021
19. Journal / agency Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE, Davidson NE, Tan-Chiu E, Martino S, Paik S, Kaufman PA, Swain SM, Pisansky TM, Fehrenbacher L, Kutteh LA, Vogel VG, Visscher DW, Yothers G, Jenkins RB, Brown AM, Dakhil SR, Mamounas EP, Lingle WL, Klein PM, Ingle JN, Wolmark N. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. The New England Journal of Medicine. October 2005. doi:10.1056/NEJMoa052122 · PMID 16236738
20. Journal / agency Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, Gianni L, Baselga J, Bell R, Jackisch C, Cameron D, Dowsett M, Barrios CH, Steger G, Huang CS, Andersson M, Inbar M, Lichinitser M, Láng I, Nitz U, Iwata H, Thomssen C, Lohrisch C, Suter TM, Rüschoff J, Suto T, Greatorex V, Ward C, Straehle C, McFadden E, Dolci MS, Gelber RD. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. The New England Journal of Medicine. October 2005. doi:10.1056/NEJMoa052306 · PMID 16236737
21. Journal / agency Joensuu H, Kellokumpu-Lehtinen PL, Bono P, Alanko T, Kataja V, Asola R, Utriainen T, Kokko R, Hemminki A, Tarkkanen M, Turpeenniemi-Hujanen T, Jyrkkiö S, Flander M, Helle L, Ingalsuo S, Johansson K, Jääskeläinen AS, Pajunen M, Rauhala M, Kaleva-Kerola J, Salminen T, Leinonen M, Elomaa I, Isola J. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. The New England Journal of Medicine. February 2006. doi:10.1056/NEJMoa053028 · PMID 16495393
22. Journal / agency Metcalfe S, Evans J, Priest G. PHARMAC funding of 9-week concurrent trastuzumab (Herceptin) for HER2-positive early breast cancer. The New Zealand Medical Journal. June 2007. PMID 17589560
23. Other 12-month Herceptin treatment now available
24. Other Breast Cancer Care Trastuzumab factsheet
25. Journal / agency Seidman A, Hudis C, Pierri MK, Shak S, Paton V, Ashby M, Murphy M, Stewart SJ, Keefe D. Cardiac dysfunction in the trastuzumab clinical trials experience. Journal of Clinical Oncology. March 2002. doi:10.1200/JCO.20.5.1215 · PMID 11870163
26. Journal / agency van Hasselt JG, Boekhout AH, Beijnen JH, Schellens JH, Huitema AD. Population pharmacokinetic-pharmacodynamic analysis of trastuzumab-associated cardiotoxicity. Clinical Pharmacology and Therapeutics. July 2011. doi:10.1038/clpt.2011.74 · PMID 21633346
27. Journal / agency Zeglinski M, Ludke A, Jassal DS, Singal PK. Trastuzumab-induced cardiac dysfunction: A 'dual-hit'. Experimental and Clinical Cardiology. 2011. PMID 22065936 · PMC3209542
28. Journal / agency Xia LY, Hu QL, Zhou Q. Use of trastuzumab in treating breast cancer during pregnancy: a systematic review and meta-analysis. BMC Women's Health. April 2021. doi:10.1186/s12905-021-01301-9 · PMID 33882925 · PMC8061001
29. Journal / agency Andrikopoulou A, Apostolidou K, Chatzinikolaou S, Bletsa G, Zografos E, Dimopoulos MA, Zagouri F. Trastuzumab administration during pregnancy: an update. BMC Cancer. April 2021. doi:10.1186/s12885-021-08162-3 · PMID 33902516 · PMC8074427
30. Journal / agency Bange J, Zwick E, Ullrich A. Molecular targets for breast cancer therapy and prevention. Nature Medicine. May 2001. doi:10.1038/87872 · PMID 11329054
31. Other Targeted Therapies for Breast Cancer Tutorial
32. Journal / agency Feldman AM, Koch WJ, Force TL. Developing strategies to link basic cardiovascular sciences with clinical drug development: another opportunity for translational sciences. Clinical Pharmacology and Therapeutics. June 2007. doi:10.1038/sj.clpt.6100160 · PMID 17392727
33. Other Winer E. HER2 Disease in the Metastatic and Adjuvant Settings
34. Journal / agency Ménard S, Pupa SM, Campiglio M, Tagliabue E. Biologic and therapeutic role of HER2 in cancer. Oncogene. September 2003. doi:10.1038/sj.onc.1206779 · PMID 14528282
35. Journal / agency Cho HS, Mason K, Ramyar KX, Stanley AM, Gabelli SB, Denney DW, Leahy DJ. Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature. February 2003. doi:10.1038/nature01392 · PMID 12610629
36. Journal / agency Drebin JA, Stern DF, Link VC, Weinberg RA, Greene MI. Monoclonal antibodies identify a cell-surface antigen associated with an activated cellular oncogene. Nature. December 1984. doi:10.1038/312545a0 · PMID 6504162
37. Journal / agency Albanell J, Codony J, Rovira A, Mellado B, Gascón P. New Trends in Cancer for the 21stCentury. 2003. doi:10.1007/978-1-4615-0081-0_21 · PMID 12908564
38. Journal / agency Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nature Medicine. April 2000. doi:10.1038/74704 · PMID 10742152
39. Other cancer.ucla.edu
40. Journal / agency Schechter AL, Stern DF, Vaidyanathan L, Decker SJ, Drebin JA, Greene MI, Weinberg RA. The neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumour antigen. Nature. December 1984. doi:10.1038/312513a0 · PMID 6095109
41. Journal / agency Drebin JA, Link VC, Weinberg RA, Greene MI. Inhibition of tumor growth by a monoclonal antibody reactive with an oncogene-encoded tumor antigen. Proceedings of the National Academy of Sciences of the United States of America. December 1986. doi:10.1073/pnas.83.23.9129 · PMID 3466178 · PMC387088
42. Other Biotechnology Breakthrough In Breast Cancer Wins FDA Approval. 25 September 1998
43. Other Altman L. Drug Is Shown to Shrink Tumors in Breast Cancer Characterized by Gene Defect. 18 May 1998
44. Other Palmer E. Mylan and Biocon finally win right to sell Herceptin biosim in India even as they have taken it to U.S. and EU. 3 March 2017
45. Journal / agency Fleck LM. The costs of caring: Who pays? Who profits? Who panders?. The Hastings Center Report. 2006. doi:10.1353/hcr.2006.0040 · PMID 16776017
46. Other Listing of Herceptin on PBS. 1 October 2006
47. Other Pharmaceutical Benefits Scheme (PBS) | Listing of Herceptin on the PBS
48. Other Emcure signs deal to manufacture Roche's anti-cancer drugs. 2 March 2012
49. Other Rajagopla D. Swiss drugmaker Roche launches costliest cancer drugs in India. 26 November 2015
50. Other Saporito, Bill. Hospitals Furious at Cancer-Drug Price Hikes. 27 October 2014
51. Journal / agency Challener C. Monoclonal Antibodies Key to Unlocking the Biosimilars Market. BioPharm International. 1 April 2014
52. Other Trastuzumab - Drugs.com
53. Other Feldges D. Brustkrebspräparat Herceptin im Fokus: Iraner kopieren Roche. 18 February 2016
54. Other Biosimilar Matches Trastuzumab in Metastatic HER2-Positive Breast Cancer. 3 June 2016
55. Journal / agency FDA approves Ogivri as a biosimilar to Herceptin. 1 December 2017
56. Other FDA approves Ogivri, first biosimilar for certain breast, stomach cancers. December 2017
57. Journal / agency Ogivri EPAR. 17 September 2018
58. Other Ogivri PI. 14 December 2018
59. Journal / agency Ontruzant EPAR. 17 September 2018
60. Other Ontruzant PI. 17 November 2017
61. Other Samsung Bioepis Receives Regulatory Approval for Europe's First Trastuzumab Biosimilar. Nov 2017
62. Journal / agency Herzuma EPAR. 17 September 2018
63. Other Herzuma PI. 13 February 2018
64. Journal / agency Drug Approval Package: Herzuma. 7 February 2019
65. Journal / agency Herzuma- trastuzumab kit; Herzuma- trastuzumab injection, powder, lyophilized, for solution. 6 February 2023
66. Journal / agency FDA approves Herzuma as a biosimilar to Herceptin. 18 December 2018
67. Journal / agency Kanjinti EPAR. 17 September 2018
68. Other Kanjinti PI. 18 May 2018
69. Journal / agency Trazimera EPAR. 17 September 2018
70. Other Summary Basis of Decision (SBD) for Ogivri. 23 October 2014
71. Other Summary Basis of Decision (SBD) for Trazimera. 23 October 2014
72. Other Summary Basis of Decision (SBD) for Herzuma. 23 October 2014
73. Other Summary Basis of Decision (SBD) for Kanjinti. 23 October 2014
74. Journal / agency Zercepac EPAR. 26 May 2020
75. Other Zercepac PI. 28 July 2020
76. Other Trastucip and Tuzucip APMDS. 29 July 2022
77. Journal / agency Herwenda: Pending EC decision. 15 September 2023
78. Journal / agency Herwenda EPAR. 15 November 2023
79. Other Herwenda Product information. 16 November 2023
80. Journal / agency Highlights of prescribing information
81. Journal / agency Tuznue EPAR. 26 July 2024
82. Other Tuznue PI. 24 September 2024
83. Other Regulatory Decision Summary for Adheroza. 20 August 2024
84. Other Summary Basis of Decision for Adheroza. 15 January 2025
85. Journal / agency Dazublys EPAR. 28 April 2025
86. Other Dazublys PI. 1 July 2025
87. Journal / agency FDA approves ado-trastuzumab emtansine for early breast cancer. 3 May 2019
88. Journal / agency FDA approves new treatment option for patients with HER2-positive breast cancer who have progressed on available therapies. 20 December 2019
89. Journal / agency FDA grants regular approval to fam-trastuzumab deruxtecan-nxki for breast cancer. 4 May 2022

Text and values on this page are quoted from Wikipedia (CC BY-SA 4.0). Each value links to the exact revision it came from.